TCIM
IMDX

TIAA CREF Investment Management’s Insight Molecular Diagnostics IMDX Stock Holding History

TIAA CREF Investment Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-370
Closed -$34K – 3052
2017
Q4 		$34K Hold
370
– – ﹤0.01% 3061
2017
Q3 		$56K Buy
370
+77
+26% +$8.06K ﹤0.01% 3077
2017
Q2 		$30K Buy
+293
New +$33.4K ﹤0.01% 3125
2016
Q2 		– Sell
-451
Closed -$42K – 3182
2016
Q1 		$42K Buy
+451
New +$39.9K ﹤0.01% 3070

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TIAA CREF Investment Management's IMDX Position: Q1 2018 in Review

TIAA CREF Investment Management sold out of Insight Molecular Diagnostics (IMDX) in Q1 2018, closing a stake of 370 shares — an estimated $34K sold.

TIAA CREF Investment Management first reported a position in IMDX in Q1 2016 and held it in 4 quarters. The position peaked at $56K in Q3 2017. 39 funds tracked by Wall St. Rank hold IMDX as of Q1 2018.

  • TIAA CREF Investment Management reported no remaining Insight Molecular Diagnostics position as of Q1 2018 after selling out during the quarter.
  • TIAA CREF Investment Management sold 370 Insight Molecular Diagnostics shares in Q1 2018, an estimated $34K.
  • TIAA CREF Investment Management first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 4 quarters.
  • TIAA CREF Investment Management's Insight Molecular Diagnostics position peaked at $56K in Q3 2017.
  • 39 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2018.

Based on TIAA CREF Investment Management's 13F filing for Q1 2018, filed 14 May 2018.